LANGUAGE
KOREANENGLISH
LOCATION
  • COMPANY
  • R&D
    • R&D Institute
    • GMP Manufacturing Facility
    • Clinical Development Status
    • Publications
  • PRODUCTS
    • 1st Generation
      • Overview
      • CARTISTEM®
      • PNEUMOSTEM®
    • 2nd Generation
      • Overview
      • SMUP-IA-01
      • SMUP-IV-01
    • R&D Inquiries
  • BUSINESS
    • CELLTREE Cord Blood Bank
    • MOVITA Nutritional Supplements
  • IR
    • Stock Information
    • Disclosure
    • Financial Information
    • IR Inquiries
  • PR
    • MEDIPOST on Media
    • Corporate Brochure
  • CONTACT US
    • Customer Center
    • R&D Inquiries
    • IR Inquiries
Star Actress Choi Jiwoo Stores Her Baby’s Umbilical Cord Blood Unit at MEDIPOST’s CELLTREE
2020/05/18
CORD BLOOD BANK

· Umbilical cord blood is rich in stem cells that can be used to treat various intractable disorders
· Umbilical cord blood-related research is gaining momentum with increasing demand for cord blood storage in light of rising life-expectancy

Korean star actress Choi Jiwoo is in the spotlight for storing her newborn baby’s umbilical cord blood, as her first gift to the baby.

MEDIPOST, a leading stem cell biotechnology company, today announced that actress Choi Jiwoo has completed a process to safely store her newborn baby’s umbilical cord blood unit at CELLTREE®, brand name of MEDIPOST’s umbilical cord blood bank.

Choi requested MEDIPOST to store her newborn baby’s umbilical cord blood in April before she gave birth to a daughter at a maternity clinic in Seoul on May 16.

Umbilical cord blood is the blood that remains in the umbilical cord and placenta following a childbirth. It is rich in hematopoietic and mesenchymal stem cells, which can be used to treat various intractable disorders.

There is a growing number of people who choose to store umbilical cord blood as a reliable lifetime insurance for their children and family members, as the average life-expectancy is reaching close to 100 years of age, as well as a growing public interest and awareness in health and well-being in the midst of the COVID-19 pandemic.

Umbilical cord blood can be safely stored for a long period thanks to cryopreservation technology using liquid nitrogen. The storage is preceded by a number of compulsory laboratory tests including cell viability, immunogenicity, microbial culture testing, and virus safety testing under the local regulations.

Korea enacted the Cord Blood Management and Research Act in 2011 to ensure public confidence in safety and quality of private cord blood banks.

The storage period can be selected by clients ranging from 15 years (minimum) to a longer-term duration. Demand for long-term storage of umbilical cord blood is on the rise with increased activities in the stem cell-related research and the expanding list of diseases which can be treated using stem cell therapy.

MEDIPOST’s CELLTREE® is Korea’s largest private cord blood bank with over 250,000 umbilical cord blood units in storage. Many celebrity couples including Kim Tae-hee & Rain, Jang Dong-Gun & Ko So-Young, and Yoo Ho-jung & Lee Jae-ryong chose CELLTREE® to store their babies’ cord blood units.

VIEW LIST

Related News

MEDIPOST starts cord blood-derived immune cell therapy development with the establishment of its subsidiary “IMMUNIQUE”2021/04/02
Longer-Term Storage of Cord Blood Gains Popularity Over 20,000 Cumulative Cases at CELLTREE2020/04/29
Korean Star Couple Rain and Kim Tae-hee Bank Baby’s Cord Blood in MEDIPOST2017/10/25
Russian Representatives of the Korea-Russia Healthcare Cooperation Group Visit MEDIPOST2017/07/26

Latest News

MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.
2022/12/01
Medipost to launch a CDMO business for cell and gene therapy products in Korea based on 20 years of research and production knowledge
2022/10/17
Canada’s OmniaBio, MEDIPOST affiliate begins CDMO cGMP for cell gene therapy
2022/10/07
MEDIPOST’s 5-year follow-up of phase 3 clinical trial patients receives 2021 OJSM award
2022/07/18
Medipost enters North American market by acquiring OmniaBio, a CDMO company with cell and gene therapy products
2022/05/31

Contacts

21, Daewangpangyo-ro 644, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea MEDIPOST Co., Ltd.
TEL : 82-2-3465-6677

CS CENTER
ONLINE INQUIRY

Latest News

·
MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.2022.12.01
·
Medipost to launch a CDMO business for cell and gene therapy products in Korea based on 20 years of research and production knowledge2022.10.17
·
Canada’s OmniaBio, MEDIPOST affiliate begins CDMO cGMP for cell gene therapy2022.10.07
·
MEDIPOST’s 5-year follow-up of phase 3 clinical trial patients receives 2021 OJSM award2022.07.18
·
Medipost enters North American market by acquiring OmniaBio, a CDMO company with cell and gene therapy products2022.05.31

Family Site

· CELLTREE Cord Blood Bank
· MOVITA Nutritional Supplements

· LOCATION
· PRIVACY POLICY

©Copyright – The Future of Biotechnology, MEDIPOST